Cancer in Norway

The 89.8 is overall survival: the share still alive five years later, from any cause. It is not the relative measure the cards for adults use, so the two are not set side by side.

“Samlet fem års overlevelse for kreft hos barn og ungdom i Norge er nå 89,8 %”

In English, Dooram's translation: “Overall five-year survival for cancer in children and young people in Norway is now 89.8 %”

Source: Folkehelseinstituttet (the Norwegian Institute of Public Health), Årsrapport 2025, Nasjonalt kvalitetsregister for barnekreft (yearly report 2025, the national quality register for childhood cancer), pages 3 and 13 of the file, read 17 October 2026.

Cancer among all deaths in 2024, in every 100

• Deaths from cancer, in every 100 deaths25.6 in 100

11,299 people died of cancer in 2024, by the final count: about one death in four. The share, 25.6 in 100 of 44,197 deaths, is Dooram's sum; the report prints the counts, not the share.

Norway's record of causes of death says:

“Kreft (ondartede svulster) har vært den hyppigste dødsårsaken i Norge siden 2017. Dette gjelder fortsatt i 2024.”

In English, Dooram's translation: “Cancer (malignant tumours) has been the most frequent cause of death in Norway since 2017. This still holds in 2024.”

Source: Folkehelseinstituttet (the Norwegian Institute of Public Health), Dødsårsaker i Norge 2024 (causes of death in Norway, 2024, from the Cause of Death Registry), pages 17, 18, 20 and 21 of the file, read 17 October 2026.

The 2025 count is early: the report says the figures may be revised.

“Dataene er foreløpige og kan bli revidert.”

In English, Dooram's translation: “The data are preliminary and may be revised.”

The 2024 count is final and comes from a different report, which counts a slightly wider set of cancers. So 11,299 and 11,703 are not two points of one line, and Dooram does not draw them as one.

Source: Folkehelseinstituttet (the Norwegian Institute of Public Health), Kreftregisteret (the Cancer Registry of Norway), Cancer in Norway 2025, pages 15 to 17 and Table 6.1, read 17 October 2026.

The measure sets people with cancer against people of the same age without it. It describes a large group and is not any one person's chance. The report prints women and men apart; both are 78.2 for every cancer.

“For alle kreftformene samlet, er fem års relativ overlevelse 78 prosent”

In English, Dooram's translation: “For all cancers together, five-year relative survival is 78 per cent”

Lung cancer is often found late: 44.8 in 100 lung cancers in men in 2021 to 2025 were found after the cancer had spread to distant parts of the body.

Source: Folkehelseinstituttet (the Norwegian Institute of Public Health), Kreftregisteret (the Cancer Registry of Norway), Cancer in Norway 2025, pages 15 and 17, and Table 4.23, read 17 October 2026.

Everyone alive who has ever had a cancer found, however long ago.

“Ved utgangen av 2025 var 359 257 personer i live etter å ha hatt minst én kreftdiagnose”

In English, Dooram's translation: “At the end of 2025, 359,257 people were alive after having had at least one cancer diagnosis”

Source: Folkehelseinstituttet (the Norwegian Institute of Public Health), Kreftregisteret (the Cancer Registry of Norway), Cancer in Norway 2025, pages 15 and 16, read 17 October 2026.

These are rates, not counts. A county with more people has more cancers, so counties are compared for every 100,000 people.

For women the counties ran from 589.8 in Finnmark to 695.3 in Telemark.

Only the highest and lowest county in each sex are drawn; the report gives all 15. No source Dooram read says why the counties differ, so Dooram does not say why either.

Source: Folkehelseinstituttet (the Norwegian Institute of Public Health), Kreftregisteret (the Cancer Registry of Norway), Cancer in Norway 2025, page 53 of the file, read 17 October 2026.

New cancers treated within a year of being found, in every 100, 2020 to 2024

• Surgery57.7
• Medicines27.8
• Radiotherapy22.6

One person can have more than one treatment, so the shares add to more than 100. The share for medicines leaves out patients from Northern Norway, as the report does.

Source: Folkehelseinstituttet (the Norwegian Institute of Public Health), Kreftregisteret (the Cancer Registry of Norway), Cancer in Norway 2025, Table 4.31, read 17 October 2026.

In the authority's words, in Nynorsk:

“Det er ni sjukehus i Noreg som tilbyr strålebehandling.”

In English, Dooram's translation: “There are nine hospitals in Norway that offer radiotherapy.”

On 13 February 2025 the authority approved Oslo University Hospital to start treating cancer patients with protons, a newer kind of radiotherapy.

The page does not name the nine hospitals.

Sources: Direktoratet for strålevern og atomsikkerhet (DSA, Norway's radiation safety authority), Strålebehandling (radiotherapy), read 17 October 2026. Direktoratet for strålevern og atomsikkerhet (DSA, Norway's radiation safety authority), DSA godkjenner oppstart av kreftbehandling med protonterapi (the authority approves the start of cancer treatment with protons), read 17 October 2026.

Breast: 78.8 in 100 of the 332,300 women invited in 2025. Bowel: of people sent a test kit in 2025, the share who sent back a sample within six months.

The goal for the cervix, in the programme's words:

“Målet er at dekningsgraden i Livmorhalsprogrammet skal være over 80%”

In English, Dooram's translation: “The aim is that coverage in the cervical programme is over 80%”

HPV is the human papillomavirus, which causes cancer of the cervix. The vaccine figures are for 16-year-olds.

Sources: Folkehelseinstituttet (the Norwegian Institute of Public Health), Mammografiprogrammet: Nøkkeltall (the breast screening programme's key figures), Tables 1 and 2, read 17 October 2026. Folkehelseinstituttet (the Norwegian Institute of Public Health), Livmorhalsprogrammet, årsrapport 2025 (the cervical screening programme's yearly report, 2025), pages 9 and 15 of the file, read 17 October 2026. Folkehelseinstituttet (the Norwegian Institute of Public Health), Tarmscreeningprogrammet, årsrapport 2025 (the bowel screening programme's yearly report, 2025), pages 6 and 16 of the file, read 17 October 2026. Folkehelseinstituttet (the Norwegian Institute of Public Health), Barnevaksinasjonsprogrammet i Norge. Årsrapport 2025 (the childhood vaccine programme's yearly report, 2025), Table 2, page 12 of the file, read 17 October 2026.

Norway's four regional health authorities decide together which new medicines their hospitals may use. A decision can be about a new medicine or a new use of one already in use.

“I 2025 var det totalt 73 (55,7 %) legemidler eller indikasjonsutvidelser innenfor sykdomskategorien kreft, hvorav 53 (72,6 %) ble innført og 20 (27,3 %) ikke innført”

In English, Dooram's translation: “In 2025 there were in all 73 (55.7 %) medicines or extended uses in the cancer category, of which 53 (72.6 %) were introduced and 20 (27.3 %) not introduced”

A decision to allow a medicine does not mean every hospital has it.

Source: Nye metoder (the national system that decides which new treatments hospitals use), Nye metoder – årsoppsummering 2025 (New Methods, summary of 2025), page 13 of the file, read 17 October 2026.